• Vera Therapeutics President and CEO Marshall Fordyce sold 18,500 Class A common shares on May 12, 2026.
• Sales priced at weighted-average USD 36.64 per share for 14,219 shares, weighted-average USD 37.09 per share for 4,281 shares.
• Directly held stake fell to 216,744 shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vera Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001859453-26-000007), on May 13, 2026, and is solely responsible for the information contained therein.